-
Autor
Abada, Paolo 1 Finn, Richard S 1 Galle, Peter R 1 Karwal, Mark 1 Kim, Tae-You 1 Koh, Su-Jin 1 Kudo, Masatoshi 1 Liang, Kun 1 Llovet, Josep M 1 Lonardi, Sara 1 Ogburn, Kenyon D 1 Pezet, Denis 1 Phelip, Jean-Marc 1 Stirnimann, Guido 1 Tomasek, Jiri 1 Touchefeu, Yann 1 Wang, Chunxiao 1 Widau, Ryan C 1 Yang, Tsai-Sheng 1 Zhu, Andrew X 1
-
Pracoviště
CHU Hôtel Dieu Nantes France 1 Chang Gung Memorial Hospital Taoyuan ... 1 Department of Internal Medicine Mainz... 1 Departments of Gastroenterology and H... 1 Division of Hematology and Oncology U... 1 Eli Lilly and Company Indianapolis IN... 1 Estaing Hospital Aubrac Clermont Ferr... 1 Institució Catalana d'Estudis Avançat... 1 Jiahui International Cancer Center Ji... 1 Masaryk Memorial Cancer Institute Mas... 1 Massachusetts General Hospital Cancer... 1 Mount Sinai Liver Cancer Program Divi... 1 Seoul National University Hospital Se... 1 Translational Research in Hepatic Onc... 1 University Hospital Inselspital and U... 1 University Hospital Saint Etienne Nor... 1 University of California Los Angeles ... 1 University of Iowa Hospitals and Clin... 1 Veneto Institute of Oncology IOV IRCC... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Abada, Paolo 1 Finn, Richard S 1 Galle, Peter R 1 Karwal, Mark 1 Kim, Tae-You 1 Koh, Su-Jin 1 Kudo, Masatoshi 1 Liang, Kun 1 Llovet, Josep M 1 Lonardi, Sara 1 Ogburn, Kenyon D 1 Pezet, Denis 1 Phelip, Jean-Marc 1 Stirnimann, Guido 1 Tomasek, Jiri 1 Touchefeu, Yann 1 Wang, Chunxiao 1 Widau, Ryan C 1 Yang, Tsai-Sheng 1 Zhu, Andrew X 1
-
Pracoviště
CHU Hôtel Dieu Nantes France 1 Chang Gung Memorial Hospital Taoyuan ... 1 Department of Internal Medicine Mainz... 1 Departments of Gastroenterology and H... 1 Division of Hematology and Oncology U... 1 Eli Lilly and Company Indianapolis IN... 1 Estaing Hospital Aubrac Clermont Ferr... 1 Institució Catalana d'Estudis Avançat... 1 Jiahui International Cancer Center Ji... 1 Masaryk Memorial Cancer Institute Mas... 1 Massachusetts General Hospital Cancer... 1 Mount Sinai Liver Cancer Program Divi... 1 Seoul National University Hospital Se... 1 Translational Research in Hepatic Onc... 1 University Hospital Inselspital and U... 1 University Hospital Saint Etienne Nor... 1 University of California Los Angeles ... 1 University of Iowa Hospitals and Clin... 1 Veneto Institute of Oncology IOV IRCC... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Galle, Peter R
- Kudo, Masatoshi
-
Llovet, Josep M
Autor Llovet, Josep M Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain Institució Catalana d'Estudis Avançats (ICREA), Barcelona, Spain
- Finn, Richard S
- Karwal, Mark
- Pezet, Denis
- Kim, Tae-You
- Yang, Tsai-Sheng
- Lonardi, Sara
- Tomasek, Jiri
NLK
Medline Complete (EBSCOhost)
od 2003-01-01 do Před 1 rokem
PubMed
34173317
DOI
10.1111/liv.14994
Knihovny.cz E-zdroje
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load. METHODS: Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre-treatment serum HBV DNA and HCV RNA were quantified using Roche COBAS AmpliPrep/COBAS TaqMan. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method and Cox proportional hazard model (stratified by study). RESULTS: Baseline characteristics were generally balanced between arms in each subgroup (HBV: N = 225, HCV: N = 127, Other: N = 190). No significant difference in treatment effect by aetiology subgroup was detected (OS interaction P-value = .23). Median OS (ramucirumab vs placebo) in months was 7.7 versus 4.5 (HR 0.74, 95% CI 0.55-0.99) for HBV, 8.2 versus 5.5 (HR 0.82, 95% CI 0.55-1.23) for HCV and 8.5 versus 5.4 (HR 0.56, 95% CI 0.40-0.79) for Other. Ramucirumab showed similar overall safety profiles across subgroups. Worst outcomes were noted in patients with a detectable HBV load. Use of HBV antiviral therapy, irrespective of viral load, was beneficial for survival, liver function and liver-specific adverse events. CONCLUSIONS: Ramucirumab improved survival across aetiology subgroups with a tolerable safety profile, supporting its use in patients with aHCC and elevated AFP.
- MeSH
- hepatocelulární karcinom * farmakoterapie MeSH
- humanizované monoklonální protilátky škodlivé účinky MeSH
- klinické zkoušky, fáze III jako téma MeSH
- lidé MeSH
- nádory jater * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.